Chapter 5 102 Table 4. Cortisol and cortisone measurements at baseline and after a 24-wk magnesium or placebo treatment (sensitivity analysis). Magnesium group (n = 25) Placebo group (n = 24) Treatment effect Baselinea 24 weeksa Baselinea 24 weeksa Adjusted effect estimateb, c P-value 24-h urinary cortisol and cortisone excretion Log cortisol, nmol/24-h 195 (171; 221) 179 (164; 196) 204 (172; 241) 206 (188; 225) 0.87 (0.77; 0.99) 0.032 Log THF, μmol/24-h 5.3 (4.7; 6.0) 4.5 (4.0; 5.0) 4.7 (3.9; 5.7) 4.8 (4.3; 5.3) 0.93 (0.79; 1.10) 0.394 Log allo-THF, μmol/24-h 2.4 (1.7; 3.4) 2.3 (2.1; 2.6) 2.7 (1.9; 3.6) 2.5 (2.2; 2.8) 0.92 (0.78; 1.09) 0.351 Log cortisone, nmol/24-h 256 (221; 291) 256 (233; 282) 261 (217; 309) 256 (233; 282) 1.00 (0.87; 1.16) 0.985 Log THE, μmol/24-h 9.5 (8.1; 10.9) 8.9 (7.9; 10.0) 8.8 (7.2; 10.9) 8.8 (7.8; 9.9) 1.01 (0.86; 1.19) 0.915 Log total production, μmol/24-h 18.4 (16.1; 20.9) 16.6 (15.0; 18.6) 17.4 (14.7; 20.7) 17.3 (15.5; 19.2) 0.97 (0.83; 1.13) 0.669 Index for A-ring reductases Log THF/allo-THF, μmol/μmol 2.1 (1.5; 2.9) 1.9 (1.7; 2.1) 1.8 (1.4; 2.6) 1.9 (1.8; 2.1) 0.96 (0.85; 1.09) 0.572 Log allo-THF/cortisol, μmol/μmol 12.5 (8.9; 16.7) 12.9 (11.7; 14.2) 12.6 (8.5; 16.6) 12.2 (11.1; 13.5) 1.05 (0.91; 1.21) 0.471 Log THF/cortisol, μmol/μmol 25.9 (23.5; 28.4) 24.7 (22.9; 26.5) 22.2 (19.7; 25.1) 23.4 (21.7; 25.2) 1.05 (0.95; 1.17) 0.317 Log THE/cortisone, μmol/μmol 35.9 (31.1; 41.4) 34.6 (31.1; 38.4) 33.2 (28.3; 39.4) 34.6 (31.0; 38.5) 1.00 (0.86; 1.16) 0.999 aValues are geometric means (95% Confidence Intervals). bValues are geometric mean ratios (95% Confidence Intervals) obtained from a oneway ANCOVA with baseline value of the dependent variable as covariate. cModels were additionally adjusted for sex. All variables were logtransformed before entering the model. Abbreviations: THF, tetrahydrocortisol; allo-THF, allo-tetrahydrocortisol; THE, tetrahydrocortisone.
RkJQdWJsaXNoZXIy MTk4NDMw